MediciNova's Phase II NASH Trial To Be Stopped Early, Shows Positive Results

MediciNova Inc. (MNOV) is terminating its phase II clinical trial of MN-001 in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with hypertriglyceridemia early based on the significant positive results from an interim analysis.

from RTT - Biotech https://ift.tt/2Ec6YKw
via IFTTT